NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RVPH

Reviva Pharmaceuticals Holdings Inc

Jul 03 • 04:00PM ET

0.3600

Dollar change -0.0250
Percentage change -6.49	%

Healthcare • Biotechnology • USA • NASD

Peers: ACAD BPMC CYTK LGND AVDL MDGL IRWD PTGX KNSA OVID

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.79	Insider Own	10.60%	Shs Outstand	68.00M	Perf Week	0.56%
Market Cap	24.48M	Forward P/E	-	EPS next Y	-0.65	Insider Trans	0.00%	Shs Float	60.79M	Perf Month	-55.86%
Enterprise Value	19.41M	PEG	-	EPS next Q	-0.13	Inst Own	16.83%	Short Float	5.66%	Perf Quarter	-35.91%
Income	-28.92M	P/S	-	EPS this Y	35.56%	Inst Trans	-4.55%	Short Ratio	2.82	Perf Half Y	-80.11%
Sales	0.00M	P/B	-	EPS next Y	-12.76%	ROA	-281.12%	Short Interest	3.44M	Perf YTD	-80.11%
Book/sh	-0.10	P/C	4.63	EPS next 5Y	22.43%	ROE	-916.17%	52W High	4.28 -91.59%	Perf Year	-69.75%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	-16.14% -	ROIC	-	52W Low	0.30 20.00%	Perf 3Y	-65.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.37% 11.82%	Perf 5Y	-96.53%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	50.61%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.54	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	30.25	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.54	EPS Q/Q	46.84%	SMA20	-44.27%	Beta	-0.07	Target Price	9.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-54.58%	Rel Volume	1.75	Prev Close	0.38
Employees	14	LT Debt/Eq	-	Earnings	May 15 AMC	SMA200	-70.86%	Avg Volume	1.22M	Price	0.36
IPO	Oct 18, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.04% -	Trades		Volume	2,136,751	Change	-6.49%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-20-23	Initiated	ROTH MKM	Buy	$12
Jun-08-23	Initiated	The Benchmark Company	Speculative Buy	$17
Jan-24-22	Initiated	H.C. Wainwright	Buy	$10

Jun-26-25 08:40AM	Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering (GlobeNewswire) -53.12%
Jun-25-25 04:17PM	Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering (GlobeNewswire) -5.12%
Jun-05-25 08:00AM	Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference (GlobeNewswire)
Jun-02-25 07:00AM	Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia (GlobeNewswire) -9.30%
May-20-25 08:00AM	Reviva to Participate in Upcoming Investor Conferences in May 2025 (GlobeNewswire) +16.85%
04:05PM	Loading…
May-15-25 04:05PM	Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +6.20%
May-13-25 08:00AM	Reviva to Participate in the A.G.P. Healthcare Company Showcase (GlobeNewswire) +7.40%
Apr-29-25 08:00AM	Reviva to Participate in the Citizens Life Sciences Conference (GlobeNewswire)
Apr-24-25 08:00AM	Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting (GlobeNewswire)
Mar-31-25 04:05PM	Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -5.56% -34.91%
Mar-30-25 11:30AM	Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress (GlobeNewswire)
Feb-04-25 08:00AM	Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-25 08:00AM	Reviva to Participate in the 2025 BIO CEO & Investor Conference (GlobeNewswire)
Jan-07-25 08:00AM	Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit (GlobeNewswire)
Dec-20-24 07:00AM	Applied Therapeutics Appoints John H. Johnson as Executive Chairman (GlobeNewswire) -10.67%
06:33AM	Loading…
Dec-19-24 06:33AM	Reviva Pharmaceuticals Strengthens Financial Position with Offering (TipRanks)
Dec-16-24 05:18PM	Reviva Announces Proposed Public Offering (GlobeNewswire) -11.88% -39.13%
08:00AM	Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia (GlobeNewswire)
Nov-14-24 05:25PM	Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -7.02%
Nov-12-24 08:00AM	Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia (GlobeNewswire) +32.00%
Nov-06-24 08:00AM	Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024 (GlobeNewswire)
Oct-31-24 08:00AM	Reviva to Participate in the UBS Global Healthcare Conference (GlobeNewswire)
Oct-08-24 08:00AM	Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-02-24 08:30AM	Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire) -9.86%
Sep-26-24 08:30AM	Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference (GlobeNewswire)
Sep-09-24 08:00AM	Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia (GlobeNewswire)
Sep-04-24 08:00AM	Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-27-24 08:00AM	Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024 (GlobeNewswire)
Aug-21-24 06:00AM	Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -25.65%
Aug-14-24 08:00AM	Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
08:00AM	Loading…
Aug-06-24 08:00AM	Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jul-09-24 08:00AM	Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension (GlobeNewswire)
May-29-24 04:45PM	Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-28-24 08:00AM	Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.80%
May-21-24 08:00AM	Reviva to Participate in the BIO International Convention (GlobeNewswire) -15.26%
May-15-24 08:00AM	Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia (GlobeNewswire) -6.30%
May-14-24 01:53PM	RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) +7.35%
08:00AM	Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-13-24 08:00AM	Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference (GlobeNewswire) -9.09%
May-09-24 08:00AM	Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting (GlobeNewswire) -24.11%
Apr-15-24 08:30AM	Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia (GlobeNewswire) -5.69%
08:05AM	Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-28-24 08:00AM	Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting (GlobeNewswire)
Mar-26-24 08:00AM	Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting (GlobeNewswire) +21.97%
Mar-11-24 08:00AM	Reviva to Present at the UBS Virtual CNS Day (GlobeNewswire) -5.14%
Mar-07-24 08:00AM	Reviva to Present at the 36th Annual ROTH Conference (GlobeNewswire)
Feb-20-24 08:00AM	Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-06-24 08:00AM	Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia (GlobeNewswire)
Jan-25-24 08:00AM	Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference (GlobeNewswire)
Jan-10-24 08:00AM	Reviva to Present at Webull LIVE! Healthcare Webinar on January 17 (ACCESSWIRE)
Jan-04-24 08:00AM	Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones (GlobeNewswire)
Dec-15-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Dec-12-23 01:02PM	Life Science Investor Forum Agenda Announced for December 14th, 2023 (GlobeNewswire)
Dec-11-23 08:35AM	Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum (GlobeNewswire)
Nov-30-23 04:05PM	Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference (GlobeNewswire)
Nov-20-23 04:05PM	Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +5.94%
Nov-16-23 08:00AM	Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -8.50%
Nov-14-23 05:23PM	Reviva Pharmaceuticals Holdings Inc Reports Q3 2023 Financial Results (GuruFocus.com) -9.19% -8.84%
04:01PM	Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-01-23 05:30AM	RVPH: RECOVER Topline (Zacks) -8.42%
Oct-30-23 07:54AM	UPDATE 1-Reviva Pharma's schizophrenia drug succeeds in late-stage study (Reuters) +46.40%
07:37AM	Reviva Pharma's schizophrenia drug succeeds in late-stage study (Reuters)
07:30AM	Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia (GlobeNewswire)
Sep-29-23 09:00AM	Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV (ACCESSWIRE)
Sep-25-23 06:00AM	Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia (GlobeNewswire)
Sep-22-23 01:30PM	Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV (ACCESSWIRE)
Sep-07-23 06:00AM	Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-18-23 06:40AM	RVPH: RECOVER Enrollment Complete (Zacks)
Aug-17-23 06:00AM	Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia (GlobeNewswire)
Aug-14-23 04:01PM	Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-02-23 12:45PM	RedChip Launches 'Small Stocks, Big Money' Podcast (ACCESSWIRE) -5.85%
Jul-31-23 08:00AM	Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August (GlobeNewswire)
Jun-26-23 06:00AM	Reviva Pharmaceuticals to be Added to Russell Microcap® Index (GlobeNewswire)
Jun-22-23 06:00AM	Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia (GlobeNewswire)
Jun-15-23 06:00AM	Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June (GlobeNewswire)
May-25-23 06:00AM	Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives (GlobeNewswire) -12.79%
May-22-23 06:30AM	Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting (GlobeNewswire)
May-19-23 06:30AM	Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform (GlobeNewswire)
May-18-23 06:30AM	Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023 (GlobeNewswire) -5.39%
May-17-23 05:41AM	RVPH: Psoriasis IND Expected (Zacks Small Cap Research)
May-15-23 04:05PM	Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) +8.86%
May-12-23 06:30AM	Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference (GlobeNewswire) -7.32%
May-11-23 06:30AM	Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data (GlobeNewswire) -6.71%
May-04-23 06:00AM	Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023 (GlobeNewswire) +7.56%
May-01-23 04:01PM	Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives (GlobeNewswire) +8.32%
Apr-25-23 07:00AM	Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia (GlobeNewswire)
Apr-20-23 04:05PM	Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry (GlobeNewswire) +7.94% +5.33%
Apr-19-23 09:00AM	Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
Apr-04-23 06:02AM	RVPH: RECOVER Parallel Studies Complete (Zacks Small Cap Research)
Mar-30-23 07:30AM	Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -10.09%
Mar-10-23 04:50AM	RVPH: Brilaroxazine Enthusiasm Abounds (Zacks Small Cap Research) -5.06%
Mar-07-23 08:00AM	Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference (GlobeNewswire)
Jan-31-23 07:09AM	We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate (Simply Wall St.) +9.93%
06:00AM	Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference (GlobeNewswire)
Jan-25-23 08:00AM	RedChip CEO Dave Gentry Invited to Join Forbes Business Council (ACCESSWIRE)
Jan-04-23 06:00AM	Reviva Pharmaceuticals Announces Letter to Shareholders (GlobeNewswire)
Dec-16-22 05:25AM	As Reviva Pharmaceuticals Holdings, Inc.'s (NASDAQ:RVPH) market cap increased US$11m, insiders who bought last year may be reflecting on buying more (Simply Wall St.) -8.76%
Dec-15-22 09:05AM	Reviva Pharmaceuticals' Schizophrenia Candidate Shows Favorable Drug-Drug Interaction Data (Benzinga)
06:00AM	Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine (GlobeNewswire)
Nov-21-22 06:00AM	Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208 (GlobeNewswire)

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RVPH

Reviva Pharmaceuticals Holdings Inc

Upgrade your FINVIZ experience